Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center Journal Article

  

Authors:	Morris, M. J.; Scher, H. I.
Article Title:	Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center
Abstract:	Hormonal therapy and chemotherapy, though active treatments for prostate cancer, are not curative for patients with metastatic disease. Targeted therapy has the potential to control, if not eradicate, cells resistant to castration and chemotherapy. Despite several years of development, however, a biologic approach with clear clinical benefits has yet to emerge from a crowded field. This review outlines the approaches being studied at Memorial Sloan-Kettering Cancer Center to optimize biologic therapy. Trials of targeted therapy are designed on the basis of a clinical states model that describes both patient clinical risks and tumor biology. Drugs that act on multiple pathways are being developed, and targets that are expressed across all phases of the disease are selected. New molecular imaging techniques permit assessments of the target before, during, and after treatment. High-throughput preclinical assays of gene expression are being developed to enhance selection of drug sequences and combinations for clinical testing. © 2003 Elsevier Science Ireland Ltd. All rights reserved.
Keywords:	signal transduction; unclassified drug; prednisone; clinical trial; doxorubicin; advanced cancer; conference paper; drug targeting; paclitaxel; research design; antineoplastic agent; carboplatin; gene expression; models, biological; etoposide; molecular dynamics; drug design; cancer research; cancer therapy; vinblastine; risk assessment; outcome assessment (health care); docetaxel; prostate cancer; prostatic neoplasms; cancer center; drug research; health status; drug mechanism; mitoxantrone; vorinostat; outcomes research; imaging; biologic therapy; ketoconazole; navelbine; clinical trials; prostate carcinoma; clinical trial design; hydroxamic acid derivative; ansamycin derivative; antisense oligonucleotide; estramustine; PET scans; humans; human; male; 17 n allylamino 17 demethoxygeldanamycin
Journal Title:	Critical Reviews in Oncology/Hematology
Volume:	46
Issue:	Suppl.
ISSN:	1040-8428
Publisher:	Elsevier Science, Inc.
Date Published:	2003-06-27
Start Page:	S21
End Page:	S31
Language:	English
DOI:	10.1016/s1040-8428(03)00061-1
PUBMED:	12850524
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-0038016527&partnerID=40&md5=d51938b16ac5fc2b615ce6fa6fef37d7
Notes:	Export Date: 25 September 2014 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/60867